Following dramatic success in many types of advanced solid tumors, interest in
immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF …

PURPOSE BRAF V600E mutations are rarely associated with objective responses to the
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …

The prognostication of colorectal cancer (CRC) has traditionally relied on staging as defined
by the Union for International Cancer Control (UICC) and American Joint Committee on …

Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …

Hereditary colorectal cancer (HCRC) accounts for< 5% of all colorectal cancer cases. Some
of the unique characteristics commonly encountered in HCRC cases include early age of …

Background Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling
currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI …

PURPOSE Early-onset (EO) colorectal cancer (CRC, age< 50 years) incidence is
increasing. Decisions on optimal adjuvant therapy should consider treatment adherence …

Current staging systems of cancer are mainly based on the anatomical extent of disease.
They need refinement by biological parameters to improve stratification of patients for tumor …